DALLAS, Nov. 4, 2014 (GLOBE NEWSWIRE) -- The worldwide glycomics market (glycobiology) is expected to grow at 12.62% CAGR and reach $928.11 Million in 2019. The key drivers for this market are the rising R &D expenditure by pharmaceutical and biotech companies, and increasing public and private funding for proteomics and glycomics research. According to the World Bank, funding for research and development activities in Asia was about $158.94 billion in 2001 and increased to $329.31 billion in 2010. Similarly, in the U.S., overall funding for research and development was about $291.77 billion in 2001, which increased to $428.94 billion in 2010. Increased funding activities are expected to positively impact the growth of the glycomics enzymes, instruments, kits, and reagents market.
Glycomics is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes such as cell recognition, immune response, cell-to-cell interaction, infection and inflammation. These processes are dependent on the intricate glycan structures present on interacting biomolecules. Advanced technologies such as high-throughput mass spectroscopy, glycan microarrays, and carbohydrate chemistry are helping to unravel the complexity resulting from this diversity.
This report ( http://www.reportsnreports.com/reports/299618-glycobiology-glycomics-market-by-product-enzymes-glycosyltransferase-neuraminidase-glycosidase-instruments-hplc-mass-spectrometry-maldi-tof-kits-and-reagents-application-immunology-oncology-by-end-user-global-forecast-to-2019.html ) segments the global glycomics market by application, end users, products, and geographies. The application segments included in this report are diagnostics; drug discovery and development; immunology; oncology; and other applications. The end-user segments of this market are academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies. The product segments included in this report are enzymes; instruments; kits; and reagents. Glycosidases; glycosyltransferases; neuraminidases; sialyltransferases; and other enzymes are subsegments of the enzymes product segment. Antibody arrays; HPLC; lectin arrays; MALDI-TOF; mass spectrometers; and other glycomics instruments are subsegments of the instruments product segment. Glycan labeling kits; glycan purification kits; glycan release kits; and other glycomics kits are subsegments of the kits market. Glycoproteins; monosaccharaides; oligosaccharides; and other glycomics reagents are subsegments of the reagents product segment.
The geographic segments included in this report are Asia, Europe, North America and Rest of the World (RoW). Asia is further divided into the regional segments of China, India, Japan, and Rest of Asia. Europe is divided into the regional segments of France, Germany, Italy, Spain, the U.K., and the Rest of Europe. North America includes Canada, and the U.S. RoW encompasses the Middle East and Africa, Pacific and Oceania, and South America.
Companies profiled in this glycomics market (glycobiology) report include Bruker Corporation, New England Biolabs, Shimadzu Corporation, Sigma-Aldrich Corporation, Takara Bio, Waters Corporation, Agilent Technologies Inc., Danaher Corporation, Prozyme and Thermo Fisher Scientific. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=299618 .
More biotechnology market reports available with ReportsnReports.com include:
The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020 according to the research titled Next Generation Sequencing (NGS) Market by Platforms (Illumina HiSeq, MiSeq, HiSeqX Ten, NextSeq 500,Thermo Fisher Ion Proton/PGM), Bioinformatics (Exome Sequencing, RNA-Seq, ChIP-Seq), Technology (SBS, SMRT) & by Application (Diagnostics, Personalized Medicine) – Global Forecast to 2020. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. Companies like 454 Life Sciences Corporation (Roche Holding Ag), Agilent Technologies Inc., Bgi (Beijing Genomics Institute), Biomatters Ltd., Clc Bio (Acquired By Qiagen), Dnastar Inc., Gatc Biotech Ag, Genomatix Software Gmbh, Illumina Inc., Knome Inc., Life Technologies Corporation (Thermo Fisher Scientific), Macrogen Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences, Partek Incorporated, Perkin Elmer, Inc. and Qiagen N.V. are profiled in this research available at http://www.reportsnreports.com/reports/257153-next-generation-sequencing-ngs-market-platforms-illumina-hiseq-miseq-life-technologies-ion-proton-pgm-454-roche-bioinformatics-rna-seq-chip-seq-pyrosequencing-sbs-smrt-diagnostics-personalized-medicine-global-forecast-to-2017.html .
Need for early diagnosis and efficient treatment with microbiome therapy for maintaining healthy lifestyle will boost the human microbiome market growth to 2023 says another research titled Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) – Global Forecast to 2023. Europe currently forms the largest human microbiome market in terms of demand for prebiotics and probiotics. The APAC region is expected to register the highest growth rate due to its immense growth opportunities and manufacturing cost benefits, while the U.S. is comparatively underdeveloped. Scientific evidence of health benefits of certain ingredients such as probiotics, prebiotics, etc. and the search for new opportunities to add value to the existing products are also expected to propel the global market growth. The demand for prebiotics and probiotics is increasing across various regions owing to the awareness among consumers regarding the favorable benefits of the microbiome community also referred as "friendly" bacteria. Most of the consumers prefer these products for maintaining good health and to use enhanced efficiency of ingredients, which offer products with biotherapeutic properties. With the advancement in technology, the usage of probiotics is likely to extend beyond the current arena of gut, dental, and immune health to several other areas of human health. Companies like Enterome Bioscience, Second Genome, Inc., Microbiome Therapeutics Llc., Vedanta Biosciences, Metabiomics Corporation, E. I. Du Pont De Nemours And Company, Merck & Co., Inc., Yakult Honsha Co., Ltd., Osel Inc. and Vithera Pharmaceuticals are profiled in this research available at http://www.reportsnreports.com/reports/297417-human-microbiome-market-by-disease-diabetes-obesity-autoimmune-cancer-diarrhea-mental-disorder-application-therapeutic-diagnostic-product-probiotic-prebiotic-food-medical-food-supplement-device-drug-global-forecast-to-2023.html .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
CONTACT: Priyank Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 email@example.com